NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES / ISSUANCE OF A NEW SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Results of RED DESERT and SAHARA proof-of-concept studies support DSR's mechanism of action as breaking the vicious cycle of cardiorenal syndrome

  60% confidence

• The tenth subscription request notice is expected to be settled into new shares on or around 21 April 2026

  60% confidence

• The drawdowns within the Facility are extending the Company's cash runway into the second quarter of 2026

  60% confidence

• Sequana Medical is commercializing the alfapump through a specialty commercial team initially targeting US liver transplant centers – 90 of these centers perform more than 90% of US liver transplants annually

  60% confidence

• All three patients from the non-randomized cohort of MOJAVE have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements

  60% confidence

• In POSEIDON study, the pivotal cohort of 40 patients implanted with alfapump showed at 6 and 24 months post-implantation the virtual elimination of therapeutic paracentesis and an improvement in quality of life

  60% confidence

• The randomized MOJAVE cohort of up to 30 further patients is dependent on securing additional financing

  60% confidence

Cited in these Via News reports

• Wave Life Sciences Obesity Trial Shows Baseline BMI Gaps Skew Efficacy Data Across Global Drug Race →